<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="131921">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01384539</url>
  </required_header>
  <id_info>
    <org_study_id>11-0521</org_study_id>
    <secondary_id>5K23DK087859</secondary_id>
    <nct_id>NCT01384539</nct_id>
  </id_info>
  <brief_title>Vitamin D and Arterial Function in Patients With Chronic Kidney Disease</brief_title>
  <official_title>Vitamin D and Arterial Function in Patients With Chronic Kidney Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether nutritional (cholecalciferol) or active
      vitamin D (calcitriol)supplementation improves vascular endothelial function in patients
      with stage IIIB and IV chronic kidney disease with vitamin D insufficiency or deficiency.
      The investigators hypothesize that the use of calcitriol supplementation will result in
      improved vascular endothelial function as compared to cholecalciferol supplementation.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference between the calcitriol and cholecalciferol groups in conduit artery endothelium-dependent dilation (EDD) in response to treatment.</measure>
    <time_frame>6 months</time_frame>
    <description>EDD measured by brachial artery flow-mediated dilation (FMD)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To compare the efficacy of calcitriol and cholecalciferol supplementation on plasma concentrations of C-reactive protein</measure>
    <time_frame>6 months</time_frame>
    <description>Secondary aims are focused to explore whether vitamin D improves vascular endothelial function through decreases in inflammation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare the effect of calcitriol and cholecalciferol supplementation on vascular endothelial cell expression of Nf-kB</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">128</enrollment>
  <condition>Arterial Dysfunction</condition>
  <condition>Chronic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>Cholecalciferol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cholecalciferol 4000 IU capsule by mouth daily x 1 month then 2000 IU capsule by mouth daily x 5 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Calcitriol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Calcitriol 0.25 mcg capsule by mouth daily x 1 month then 0.5 mcg capsule by mouth daily x 5 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cholecalciferol</intervention_name>
    <arm_group_label>Cholecalciferol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calcitriol</intervention_name>
    <arm_group_label>Calcitriol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age â‰¥ 18 years

          -  Chronic kidney disease stage IIIB or IV by 4 parameter Modified Diet in Renal
             Diseases Formula (Estimated Glomerular Filtration Rate [GFR] 44-15 ml/min/1.73m2)

          -  Vitamin D (D2 + D3) deficient, defined as serum 25(OH)D level &lt; 30 ng/mL

          -  Corrected serum calcium &lt; 10.2 mg/dL

          -  Serum phosphate &lt; 4.6 mg/dL

          -  Serum albumin &gt; 3.0 g/dL

          -  Body mass index &lt; 40 kg/m2

          -  Ability to give informed consent

        Exclusion Criteria:

          -  Significant co-morbid conditions that lead the investigator to conclude that life
             expectancy is less than 1 year

          -  Expected to undergo living related kidney transplant in next 6 months

          -  Pregnant, breastfeeding, or unwilling to use adequate birth control

          -  History of severe liver disease

          -  Nephrotic range proteinuria (&gt; 3.5 gm/day)

          -  Use of active vitamin D analogs within 30 days of randomization
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jessica Kendrick, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Colorado Denver Clinical Translational Research Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <lastchanged_date>August 5, 2016</lastchanged_date>
  <firstreceived_date>June 27, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>chronic kidney disease</keyword>
  <keyword>vitamin D deficiency</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Calcitriol</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
